Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease

Overview

The purpose of this study is to determine whether simvastatin is effective in reducing the frequency and intensity of vaso-occlusive pain episodes in patients with sickle cell disease.

Full Title of Study: “Phase 2 Study of Simvastatin Treatment Effects on Vaso-occlusive Pain in Sickle Cell Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2015

Detailed Description

Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive episodes and a chronic inflammatory state leading to progressive multi-organ injury. The pathophysiology of SCD is related to endothelial dysfunction driven largely by impaired nitric oxide (NO) homeostasis and chronic inflammation. Through multiple mechanisms, including upregulation of NO, statins have been shown to confer protection from endothelial injury, independent of their cholesterol-lowering properties. By inhibiting inflammation and several common pathways leading to vascular damage,simvastatin may help prevent the acute and chronic complications of SCD. The objective of this study is to determine whether our preliminary results showing simvastatin-associated reductions in plasma markers of vascular injury will translate into a reduction in vaso-occlusive pain episodes in patients with SCD. A web-based, smartphone-accessible electronic pain diary will be used to monitor frequency and intensity of vaso-occlusive pain in SCD patients treated with a single daily dose of simvastatin.

Interventions

  • Drug: Simvastatin
    • 40 mg, orally, once daily for 3 months

Arms, Groups and Cohorts

  • Experimental: simvastatin
    • Simvastatin (Zocor), 40mg tablet, 40mg orally once daily, for 3 months

Clinical Trial Outcome Measures

Primary Measures

  • Change in Frequency of Vaso-occlusive Pain Events, Before and After Treatment With Simvastatin
    • Time Frame: Baseline and 3 months
    • The effect of simvastatin treatment will be assessed by measuring the difference from baseline in the mean frequency (and intensity) of vaso-occlusive pain events, after treatment with simvastatin. Pain rate (proportion of pain days) was defined as the number of days reported with sickle cell disease-related pain divided by the number of daily pain diaries completed.

Secondary Measures

  • Change in Plasma High Sensitivity C-reactive Protein
    • Time Frame: Baseline and 3 months
    • Mean difference in plasma high sensitivity C-reactive protein level, before and after treatment with simvastatin
  • Change From Baseline in Total Cholesterol Level After Treatment With Simvastatin
    • Time Frame: Baseline and 3 months

Participating in This Clinical Trial

Inclusion Criteria

  • Sickle cell disease (HbSS or S/β0 thalassemia) – ≥ 3 vaso-occlusive pain episodes in the year prior to enrollment – Age ≥ 10 years – Weight > 30 kg Exclusion Criteria:

  • Creatine kinase (CK) > UNL – Total cholesterol < 90 mg/dL, or triglycerides <30mg/dL – Renal dysfunction (Creatinine > 1.5-fold UNL) – Hepatic dysfunction (ALT > 2-fold UNL) – Treatment with drugs having known metabolic interactions with statins within the past 30 days – Vaso-occlusive pain requiring hospitalization within past 30 days – Red blood cell transfusion within the past 30 days – Pregnancy/lactation – Musculoskeletal disorder associated with an elevated CK level – Past or present history of substance abuse (alcohol, cocaine, amphetamines, heroin) – Chronic pain caused by avascular necrosis of the bone (AVN) or leg ulcers, and pain due to trauma or causes other than SCD. – Major cognitive or neurological impairments that may hamper the ability to use the smartphone or complete the electronic pain diary in this study

Gender Eligibility: All

Minimum Age: 10 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • UCSF Benioff Children’s Hospital Oakland
  • Collaborator
    • University of California, Los Angeles
  • Provider of Information About this Clinical Study
    • Principal Investigator: Carolyn Hoppe, Associate Hematologist-Oncologist – UCSF Benioff Children’s Hospital Oakland
  • Overall Official(s)
    • Carolyn Hoppe, MD, Principal Investigator, UCSF Benioff Children’s Hospital Oakland

References

Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011 Jun;153(5):655-63. doi: 10.1111/j.1365-2141.2010.08480.x. Epub 2011 Apr 8.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.